Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States

摘要

The GALLIUM trial compared obinutuzumab (GA101, G)-based chemotherapy followed by G monotherapy (G?+?chemo) for up to two years to rituximab (R)-based chemotherapy followed by R monotherapy (R?+?chemo) for up to two years in previously untreated follicular lymphoma (FL) patients. We estimated the cost-effectiveness of G?+?chemo versus R?+?chemo utilizing GALLIUM trial data and published literature. G?+?chemo had increased drug costs (undiscounted: $135,200 versus $127,700 for R?+?chemo), representing a relative increase of 5.9%. However, this was offset by a $6,400 lower cost for disease progression. G?+?chemo led to increased quality-adjusted life years (QALYs) relative to R?+?chemo of 0.81 (95% credible range, [CR]: 0.22–1.37), and the overall discounted incremental cost was $1,900 (95% CR: ?$7,400 to $8,900). The incremental cost-effectiveness ratio was ～$2,300 per QALY gained, and the results were highly robust to sensitivity analyses. Treatment with G?+?chemo compared to R?+?chemo is cost-effective in previously untreated FL patients in the US.